Drugs / Quavonlimab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03179436 | Jul 2017 → Apr 2024 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04740307 | Mar 2021 → Jul 2025 | hepatocellular carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03516981 | Oct 2018 → Jun 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740307 ↗ |
| Known as | MK-1308 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650419 ↗ |
| Known as | QUAVONLIMAB COMPONENT OF MK-1308A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650419 ↗ |
| Action | Inhibit | “anti-CTLA-4 quavonlimab” PMID 37429923 ↗ Jul 2023 |
| Modality | Monoclonal antibody | “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab” PMID 34371366 ↗ Jul 2021 |
| Route | Intravenous | “Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy...” NCT03179436 ↗ |
| Target | CTLA4 | “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab” PMID 34371366 ↗ Jul 2021 |